<DOC>
	<DOC>NCT01741545</DOC>
	<brief_summary>The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA &lt; LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3</brief_summary>
	<brief_title>Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Severe hemophilia (defined as &lt; 1% factor activity level) Infection with the hepatitis C virus (HCV) with underlying hemophilia Males 18 years of age and above Have not been previously treated with an interferon Not infected with the hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Chronic liver disease caused by any disease other than chronic HCV infection Presence of Bethesda inhibitor Current evidence of or history of portal hypertension</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>